Westfield Capital Management Co. LP Has $41.89 Million Stock Holdings in Bicycle Therapeutics plc (NASDAQ:BCYC)

Westfield Capital Management Co. LP boosted its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 21.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,850,945 shares of the company's stock after buying an additional 327,089 shares during the period. Westfield Capital Management Co. LP owned approximately 3.90% of Bicycle Therapeutics worth $41,887,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Avoro Capital Advisors LLC purchased a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at $14,168,000. Perceptive Advisors LLC acquired a new stake in Bicycle Therapeutics in the 2nd quarter valued at $11,577,000. Principal Financial Group Inc. purchased a new position in Bicycle Therapeutics in the third quarter valued at about $10,028,000. Armistice Capital LLC lifted its stake in shares of Bicycle Therapeutics by 17.9% during the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company's stock worth $39,913,000 after purchasing an additional 300,000 shares in the last quarter. Finally, First Light Asset Management LLC boosted its position in shares of Bicycle Therapeutics by 16.1% in the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company's stock worth $28,028,000 after buying an additional 191,717 shares during the period. 86.15% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on BCYC shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Bicycle Therapeutics in a report on Monday, September 9th. Needham & Company LLC restated a "buy" rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Royal Bank of Canada restated an "outperform" rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. HC Wainwright restated a "buy" rating and set a $55.00 price target on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Finally, Stephens assumed coverage on Bicycle Therapeutics in a research report on Friday, November 8th. They set an "equal weight" rating and a $25.00 price objective for the company. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Bicycle Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $40.13.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,212 shares of the company's stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total transaction of $71,499.12. Following the sale, the chief executive officer now directly owns 380,864 shares of the company's stock, valued at approximately $8,478,032.64. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Travis Alvin Thompson sold 6,256 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the sale, the chief accounting officer now directly owns 19,241 shares of the company's stock, valued at approximately $483,141.51. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,840 shares of company stock worth $259,128 in the last three months. Insiders own 8.50% of the company's stock.

Bicycle Therapeutics Stock Down 2.9 %

BCYC traded down $0.59 during midday trading on Monday, reaching $19.95. 228,642 shares of the company's stock were exchanged, compared to its average volume of 361,515. Bicycle Therapeutics plc has a one year low of $13.31 and a one year high of $28.67. The business has a 50-day simple moving average of $23.97 and a two-hundred day simple moving average of $23.03. The firm has a market capitalization of $948.62 million, a price-to-earnings ratio of -6.35 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same quarter in the previous year, the company posted ($1.26) EPS. The business's revenue for the quarter was down 50.0% compared to the same quarter last year. As a group, research analysts anticipate that Bicycle Therapeutics plc will post -3.07 EPS for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.